Mitoxantrone Versus Liposomal Daunorubicin in Induction of Pediatric AML With Risk Stratification Based on Flow Cytometry Measurement of Residual Disease
Journal of Clinical Oncology · 2024
DOI: 10.1200/jco.23.01841 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Journal of Clinical Oncology, 2024. Verfasst von Anne Tierens und 17 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory Medicine Program, University Health Network, Toronto General Hospital, Toronto, ON, Canada. Hauptthemen laut MEDLINE: Mitoxantrone, Daunorubicin, Neoplasm, Residual, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 31 Literaturangaben.
Abstract (Originalsprache)
PURPOSE Measurable residual disease (MRD) by using flow cytometry after induction therapy is strongly prognostic in pediatric AML, and hematopoietic stem-cell transplant (hSCT) may counteract a poor response. We designed a phase III study with intensified response-guided induction and MRD-based risk stratification and treated poor induction response with hSCT. The efficacy of liposomal daunorubicin (DNX) in induction was compared with mitoxantrone. METHODS The study planned to randomly assign 300 patients, but the production of DNX ceased in 2017. One hundred ninety-four patients were randomly assigned to mitoxantrone or experimental DNX in induction 1. Ninety-three non–randomly assigned patients served as an observation cohort. Primary end point was fraction of patients with MRD
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Laboratory Medicine Program, University Health Network, Toronto General Hospital, Toronto, ON, Canada.
- Department of Pediatric Hemato-Oncology, Rambam Health Care Campus, Haifa, Israel.
- Department of Pediatrics and Adolescent Medicine, Hong Kong Children's Hospital and Hong Kong Pediatric Hematology and Oncology Study Group (HKPHOSG), Hong Kong, China.
- Department of Pediatric Hematology-Oncology, Ghent University Hospital, Gent, Belgium.
- Department of Pediatric Hemato-Oncology, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
- Department of Pediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark.
ORCID-Profile: Anne Tierens, Nira Arad-Cohen, Barbara De Moerloose, Henrik Hasle, Kirsi Jahnukainen, Gertjan Kaspers, Birgitte Lausen, Josefine Palle, Cornelis Jan Pronk, Bernward Zeller, Jonas Abrahamsson
Zitieren
APA
Tierens, A., Arad-Cohen, N., Cheuk, D., De Moerloose, B., Fernandez Navarro, J. M., Hasle, H., Jahnukainen, K., Juul-Dam, K. L., Kaspers, G., Kovalova, Z., Lausen, B., Norén-Nyström, U., Palle, J., Pasauliene, R., Jan Pronk, C., Saks, K., Zeller, B., & Abrahamsson, J. (2024). Mitoxantrone Versus Liposomal Daunorubicin in Induction of Pediatric AML With Risk Stratification Based on Flow Cytometry Measurement of Residual Disease. Journal of Clinical Oncology. https://doi.org/10.1200/jco.23.01841
Vancouver
Tierens A, Arad-Cohen N, Cheuk D, De Moerloose B, Fernandez Navarro JM, Hasle H, et al. Mitoxantrone Versus Liposomal Daunorubicin in Induction of Pediatric AML With Risk Stratification Based on Flow Cytometry Measurement of Residual Disease. Journal of Clinical Oncology. 2024. doi:10.1200/jco.23.01841
BibTeX
@article{Tierens2024,
author = {Tierens, Anne and Arad-Cohen, Nira and Cheuk, Daniel and De Moerloose, Barbara and Fernandez Navarro, Jose Maria and Hasle, Henrik and Jahnukainen, Kirsi and Juul-Dam, Kristian Løvvik and Kaspers, Gertjan and Kovalova, Zanna and Lausen, Birgitte and Norén-Nyström, Ulrika and Palle, Josefine and Pasauliene, Ramune and Jan Pronk, Cornelis and Saks, Kadri and Zeller, Bernward and Abrahamsson, Jonas},
title = {Mitoxantrone Versus Liposomal Daunorubicin in Induction of Pediatric AML With Risk Stratification Based on Flow Cytometry Measurement of Residual Disease},
journal = {Journal of Clinical Oncology},
year = {2024},
doi = {10.1200/jco.23.01841}
}
EUVIMED